In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Valneva SE

Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease

Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.

Clinical Trials Business Strategies

Sylentis Piles On Another Failure In Dry Eye

The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.

Clinical Trials Ophthalmic

What’s In Store For Sun’s Key Specialty Drugs Including Melanoma Asset

An "uncontested market" in the neoadjuvant setting potentially awaits Sun’s partnered melanoma asset Nidlegy, while competition heats up for products like Cequa in the US. Scrip pieces together management commentary and analysts’ outlook on some of the key specialty therapies that India’s top-ranked drug maker is building out.

Commercial Business Strategies

Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024

Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.

Financing Business Strategies
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • BliNK Biomedical SAS
    • Crucell Sweden AB
    • Iomai Corporation
    • Intercell USA, Inc.
    • Intercell AG, Vivalis
UsernamePublicRestriction

Register